These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12542927)

  • 1. Economic consequences of antimicrobial resistance.
    Paladino JA; Sunderlin JL; Price CS; Schentag JJ
    Surg Infect (Larchmt); 2002; 3(3):259-67. PubMed ID: 12542927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and economic burden of antimicrobial resistance.
    Maragakis LL; Perencevich EN; Cosgrove SE
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):751-63. PubMed ID: 18847410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct medical costs associated with using vancomycin in methicillin-resistant Staphylococcus aureus infections: an economic model.
    Shah NP; Reddy P; Paladino JA; McKinnon PS; Klepser ME; Pashos CL
    Curr Med Res Opin; 2004 Jun; 20(6):779-90. PubMed ID: 15200734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs.
    Cosgrove SE
    Clin Infect Dis; 2006 Jan; 42 Suppl 2():S82-9. PubMed ID: 16355321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current challenges in the management of the infected patient.
    Nicolau DP
    Curr Opin Infect Dis; 2011 Feb; 24 Suppl 1():S1-10. PubMed ID: 21200179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial stewardship: bridging the gap between quality care and cost.
    Goff DA
    Curr Opin Infect Dis; 2011 Feb; 24 Suppl 1():S11-20. PubMed ID: 21200180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship.
    Roberts RR; Hota B; Ahmad I; Scott RD; Foster SD; Abbasi F; Schabowski S; Kampe LM; Ciavarella GG; Supino M; Naples J; Cordell R; Levy SB; Weinstein RA
    Clin Infect Dis; 2009 Oct; 49(8):1175-84. PubMed ID: 19739972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact and relevance of antibiotic resistance.
    French GL
    Adv Drug Deliv Rev; 2005 Jul; 57(10):1514-27. PubMed ID: 15978698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved antimicrobial interventions have benefits.
    Barenfanger J; Short MA; Groesch AA
    J Clin Microbiol; 2001 Aug; 39(8):2823-8. PubMed ID: 11473998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High cost burden and health consequences of antibiotic resistance: the price to pay.
    Chandy SJ; Naik GS; Balaji V; Jeyaseelan V; Thomas K; Lundborg CS
    J Infect Dev Ctries; 2014 Sep; 8(9):1096-102. PubMed ID: 25212073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of antimicrobial resistance on health and economic outcomes.
    Cosgrove SE; Carmeli Y
    Clin Infect Dis; 2003 Jun; 36(11):1433-7. PubMed ID: 12766839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Burden of antimicrobial resistance in an era of decreasing susceptibility.
    Tillotson GS; Zinner SH
    Expert Rev Anti Infect Ther; 2017 Jul; 15(7):663-676. PubMed ID: 28580804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economics of antibiotic resistance.
    Sipahi OR
    Expert Rev Anti Infect Ther; 2008 Aug; 6(4):523-39. PubMed ID: 18662118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The negative impact of antibiotic resistance.
    Friedman ND; Temkin E; Carmeli Y
    Clin Microbiol Infect; 2016 May; 22(5):416-22. PubMed ID: 26706614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, poland--part I.
    Kusowska J
    Acta Pol Pharm; 2005; 62(6):485-90. PubMed ID: 16583989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, Poland--part II.
    Kusowska J
    Acta Pol Pharm; 2005; 62(6):491-5. PubMed ID: 16583990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotic resistance as a major public health concern: epidemiology and economic impact.
    Ciorba V; Odone A; Veronesi L; Pasquarella C; Signorelli C
    Ann Ig; 2015; 27(3):562-79. PubMed ID: 26152543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomics of appropriate antimicrobial use.
    Davey P
    Diagn Microbiol Infect Dis; 1995; 22(1-2):225-9. PubMed ID: 7587044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic burden of antibiotic resistance: how much do we really know?
    Gandra S; Barter DM; Laxminarayan R
    Clin Microbiol Infect; 2014 Oct; 20(10):973-80. PubMed ID: 25273968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacoeconomics of infection in the intensive care unit].
    Grau S; Alvarez-Lerma F
    Rev Esp Quimioter; 2008; 21 Spec No 1():26-34. PubMed ID: 18752077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.